Pr KOHLI Evelyne

Fiche personne

Coordonnées

Centre de Recherche INSERM LNC-UMR1231
7 bd Jeanne d'Arc
BP 87900
21079 DIJON Cedex

Territoire

Bourgogne

Statut

Hospitalo-Universitaire

Affiliation

Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Inserm UMR 1231 "Centre de recherche translationnelle en médecine moléculaire (CTM)" (Inserm UMR1231 CTM)

Université de Bourgogne (UB)

Équipes/plateformes

Equipe UMR 1231 - Equipe "Protéines de choc thermique : mort cellulaire, différenciation cellulaire et propriétés tumorigéniques (HSP-pathies)"

Recherche

Expertises :
- Clinique:Pharmacie

Publications

Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model.

Bellaye PS, Dias AM, Vrigneaud JM, Bouchard A, Moreau M, Petitot C, Bernhard C, Claron M, Froidurot L, Morgand V, Guillemin M, Monterrat M, Mirjolet C, Garrido C, Kohli E, Collin B

Heliyon. 2024 10 30;10(20):e39543

Are genetically modified protozoa eligible for ATMP status? Concerning the legal categorization of an oncolytic protozoan drug candidate.

Guerriaud M, Poupet C, Lakhrif Z, Kohli E, Moiré N

Gene Ther. 2024 03 1;:

The endoplasmic reticulum stress protein GRP94 modulates cathepsin L activity in M2 macrophages in conditions of obesity-associated inflammation and contributes to their pro-inflammatory profile.

Wang F, Baverel V, Chaumonnot K, Bourragat A, Bellenger J, Bellenger S, Zhou W, Narce M, Garrido C, Kohli E

Int J Obes (Lond). 2024 02 13;:

Superparamagnetic Iron Oxide Nanoparticles for Immunotherapy of Cancers through Macrophages and Magnetic Hyperthermia.

Dias AMM, Courteau A, Bellaye PS, Kohli E, Oudot A, Doulain PE, Petitot C, Walker PM, Decréau R, Collin B

Pharmaceutics. 2022 11 5;14(11):

RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation.

Guerriaud M, Kohli E

Front Med (Lausanne). 2022 10 17;9:1012497

Buprenorphine reduces methamphetamine intake and drug seeking behavior activating nociceptin/orphanin FQ peptide receptor in rats.

Wang F, Shen W, Cai Y, Zhang X, Du H, Lai M, Liu H, Kohli E, Zhou W

Front Psychiatry. 2022 10 6;13:983595

The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with Tc-Tilmanocept SPECT.

Bouchard A, Sikner H, Baverel V, Garnier AR, Monterrat M, Moreau M, Limagne E, Garrido C, Kohli E, Collin B, Bellaye PS

Cells. 2021 12 2;10(12):

Endoplasmic Reticulum Chaperones in Viral Infection: Therapeutic Perspectives.

Kohli E, Causse S, Baverel V, Dubrez L, Borges-Bonan N, Demidov O, Garrido C

Microbiol Mol Biol Rev. 2021 Oct 13;:e0003521

Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.

Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E

Vaccines (Basel). 2021 Oct 6;9(10):

GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment.

Bouchard A, Collin B, Garrido C, Bellaye PS, Kohli E

Biology (Basel). 2021 Aug 27;10(9):

Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis.

Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E

Vaccines (Basel). 2021 Aug 9;9(8):

The HSP GRP94 interacts with macrophage intracellular complement C3 and impacts M2 profile during ER stress.

Chaumonnot K, Masson S, Sikner H, Bouchard A, Baverel V, Bellaye PS, Collin B, Garrido C, Kohli E

Cell Death Dis. 2021 Jan 22;12(1):114

Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease.

Seignez A, Joly AL, Chaumonnot K, Hazoumé A, Sanka M, Marcion G, Boudesco C, Hammann A, Seigneuric R, Jégo G, Ducoroy P, Delarue P, Senet P, Castilla-Llorente C, Solary E, Durey MA, Rubio MT, Hermine O, Kohli E, Garrido C

JCI Insight. 2017 Mar;2(6):e90531

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

Joly AL, Deepti A, Seignez A, Goloudina A, Hebrard S, Schmitt E, Richaud S, Fourmaux E, Hammann A, Collura A, Svrcek M, Jego G, Robinet E, Solary E, Demidov O, Kohli E, Garrido C

Oncogene. 2016 Jun;35(22):2948

B subunits of cholera toxin and thermolabile enterotoxin of Escherichia coli have similar adjuvant effect as whole molecules on rotavirus 2/6-VLP specific antibody responses and induce a Th17-like response after intrarectal immunization.

Thiam F, Charpilienne A, Poncet D, Kohli E, Basset C

Microb. Pathog.. 2015 Dec;89:27-34

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

Joly AL, Deepti A, Seignez A, Goloudina A, Hebrard S, Schmitt E, Richaud S, Fourmaux E, Hammann A, Collura A, Svrcek M, Jego G, Robinet E, Solary E, Demidov O, Kohli E, Garrido C

Oncogene. 2015 Sep 14